Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfs25-IMX313/Matrix-M for Malaria in Tanzania
NCT04271306Phase 1Terminated
- Sponsor
- University of Oxford
- Start
- May 2021
- Primary completion
- Feb 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pfs25-IMX313 in malaria (6 arms), sponsored by University of Oxford. Primary endpoints: Safety of Pfs25IMX313-Matrix-M (Solicited symptoms), Safety of Pfs25IMX313-Matrix-M (Unsolicited symptoms) and 1 more. Started May 2021; status: terminated.
02
Drugs
Pfs25-IMX313
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04271306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271306.